Structure Therapeutics Inc.
21.19USD
-0.7400 (-3.37%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on GPCR.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | — | — | — | 41.7M | 45.5K |
| Q1 | — | — | — | — | — | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | 50.0M | — |
| Q4 | — | — | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.501 | -.810 | -.780 | -.800 | -1.62 | -2.19 |
| Q1 | -.131 | -.250 | -.190 | -.270 | -.350 | — |
| Q2 | -.149 | -.200 | -.180 | -.360 | -.490 | — |
| Q3 | -.115 | -.210 | -.200 | -.370 | -.241 | — |
| Q4 | -.113* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.222* |
| -.231* |
| .186* |
| -.490 |
| — |
Debt level and coverage